Navigation Links
The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

LOVENOX(R) should be used with extreme caution. Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm3, LOVENOX(R) should be discontinued. Cases of heparin-induced thrombocytopenia have been observed in clinical practice. (See WARNINGS).

The use of LOVENOX(R) has not been adequately studied for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves. (See WARNINGS).

LOVENOX(R) is contraindicated in patients with hypersensitivity to enoxaparin sodium, heparin, or pork products, and in patients with active major bleeding.

Please see accompanying full prescribing information including boxed WARNING.

Please visit http://www.lovenox.com for complete prescribing information, including boxed WARNING, and additional important information.

About sanofi-aventis

Sanofi-aventis is one of the world's leading pharmaceutical companies. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
3. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
4. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
5. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
8. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
9. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:9/1/2015)... LAVAL, Quebec , Sept. 1, 2015 /PRNewswire/ ... and TSX: VRX) today announced that its affiliate ... under which Valeant was granted an exclusive license ... Brodalumab is an IL-17 receptor monoclonal antibody in ... psoriatic arthritis. Under the agreement, Valeant will hold ...
(Date:8/31/2015)... 31, 2015  DICOM Grid,  the #1 medical ... was recognized as a semifinalist for a Minnie ... The awards are sponsored by Auntminnie.com, a comprehensive ... the medical imaging industry.  Since 1999, the "Minnies" ... acknowledge the contributions of their peers. Nominations are ...
(Date:8/31/2015)... 2015  Chiasma, Inc. (NASDAQ: CHMA ), ... for the orphan condition acromegaly, today reported financial ... 2015 and provided a corporate update. ... time for Chiasma, as we successfully completed our ... first New Drug Application (NDA) has been accepted ...
Breaking Medicine Technology:Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9
(Date:9/1/2015)... ... September 01, 2015 , ... ... a next-generation customer communications archiving solution integrated with Alfresco‘s enterprise content management ... and helps organizations save millions of dollars in printing costs by digitizing ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Elizabeth Callahan, MD, ... of the first in the area to offer RADIESSE® filler treatment for volume loss ... the prominence of tendons and veins in the hands, delivering smooth, natural-looking results that ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices ... take a look at the topic of arthritis. There are over 100 different types ... interesting arthritis types and statistics in an effort to shed light on this important ...
(Date:9/1/2015)... ... 01, 2015 , ... Specialty Technical Publishers (STP) and Specialty ... Consortium (IAPC) EHS audit protocol for the European Union. Leading companies around the ... regulatory obligations and rapidly collect, share, archive, and export audit findings in a ...
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, provider of CEUs ... hours of new premium on-demand video Evidence Based Practice courses ... before 2014 must complete 50 CEUs before December 31, 2015, which must include ...
Breaking Medicine News(10 mins):Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2
... a fundamental practice for limiting the spread of ... in African countries, including Kenya, have shown that ... acquiring HIV from an infected woman. The challenge ... a public-health strategy that can save millions of ...
... Gehrig,s disease , , MONDAY, Nov. 24 (HealthDay News) -- ... showed no benefit for people with amyotrophic lateral sclerosis ... two-year U.S. study included 330 patients from 20 medical ... results. One North American study found that IGF-1 was ...
... CINCINNATI, Nov. 24 Dr. Stephen Joffe, Craig Joffe, ... 13D with the U.S.,Securities and Exchange Commission. The ... LCA-Vision, Inc. (Nasdaq: LCAV ), which,operates 77 ... the United States. Dr. Joffe is the founder ...
... talk about eating healthfully, they make healthy foods, too. Members ... (FCP) practice group participated in a 2008 "Fast, Fresh & ... to the top three submissions that were both healthy and ... for the contest recipes were that they must include at ...
... SEATTLE, Nov. 24 Bulimics are notorious for hiding their disease. ... secret disease. You inflict it upon yourself..." Hiding the signs becomes ... that is. , , "The ... wrong are everywhere - swollen salivary glands, stomach-acid etched teeth," says ...
... focus on radiology IT drives a strong return on investment ... Nov. 24 AMICAS, Inc. (Nasdaq: AMCS ), ... solutions, today announced that it will highlight the AMICAS ONE ... cycle management, teleradiology, and document management, at the 2008 Radiological ...
Cached Medicine News:Health News:US$18.5 million grant makes male circumcision a top-tier HIV prevention strategy 2Health News:US$18.5 million grant makes male circumcision a top-tier HIV prevention strategy 3Health News:Growth Hormone Won't Fight ALS 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 6Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 7Health News:Three Chef-Dietitians Win CanolaInfo Recipe Contest 2Health News:Bulimia Can't Hide From This Dentist 2Health News:AMICAS Showcases Comprehensive Image and Information Management Solution Suite at RSNA 2Health News:AMICAS Showcases Comprehensive Image and Information Management Solution Suite at RSNA 3
... an in-line, battery-powered disposable, lightweight and completely ... capable of intravenous application and irrigation warming. ... to help prevent fluid-induced hypothermia. The ... 38°C (100.4°F) 3°C at a flow rate ...
Using the patient's own blood pressure as the driving force, CAVR circulates cold blood through the Level 1 heat exchanger and returns it to the patient at body temperature for rapid core rewarming....
... a ruggedly built, simple to operate fluid warmer ... controlled warming of blood or other fluids being ... by a water reservoir which is heated by ... which is backed up by a thermoswitch. Blood ...
... clinicians., ,Building off the proven technology ... MRI is one of the few MRI ... integrated ventilator. Validated for use the MRI ... magnet), the Aestiva/5 MRI uses the same ...
Medicine Products: